Sunao Fujioka obtained his master’s degree in pharmaceutical sciences
at the University of Tokyo. He started his career at McKinsey & Company
Japan office, then moved to Janssen Pharmaceuticals, and most
recently at MSD, mainly in charge of marketing / business operations.
At MSD, he has led launch of the biomarker / diagnostic field in the oncology business, developed and accelerated novel biomarkers / companion diagnostic adoption in Japan market with relevance to immune-checkpoint inhibitors, such as PD-L1, MSI, etc. He also has marketing experiences in vaccines, gynecologic cancers, breast cancers, and hematology.
He joined bitBiome Inc. in August 2019 and took on his current role in March 2020.
Masahito Hosokawa received his Ph.D. in Engineering from Tokyo
University of Agriculture and Technology in 2010.
After a postdoctoral training at Shizuoka Cancer Center between 2011 and 2013, he moved to Waseda University in 2013 and started single-cell research as a JST-PRESTO researcher in 2015.
His research focuses on developing and applying novel microfluidic tools for single-cell genomics and transcriptomics. He founded bitBiome Inc. in 2018 based on his single-cell genomics platform. He has received major awards including The Young Scientists’ Prize by Minister of Education, Culture, Sports, Science and Technology (2019) and the JST PRESTO Innovation Award (2019).
He also works as an adjunct researcher at Waseda University.
Kimihiko Sato obtained his master’s degree in molecular biology at the
University of Tokyo. He started his career at Mitsui Sumitomo Insurance
Company, in the product development department working on actuarial
He then worked as a management consultant at Boston Consulting Group for seven years, specific to the healthcare industry. Managing a team as a Project Leader, he developed and implemented a broad range of strategies such as mid/long-term corporate growth, new product launch, sales, and manufacturing.
He joined bitBiome Inc. in February 2020 and took on his current role in March 2020.
Yoshihito Daimon graduated from microbial technology and genetic resources
engineering at Kyushu University Graduate School and engaged in intellectual
property (IP) and legal at Astellas Pharma Inc.
Then he transferred to Astellas US and was in charge of M&A and many alliances. In IP litigations in a pharmaceutical field, he has engaged in 12 trials with 12 wins and 0 loss and contributed to the business to produce profits of over 10 billion yen through his outstanding skills related to pharmaceutical legal and IP strategies.
In recent years, he has been working as a founding supporter who helps many life-sciences startups from the perspective of legal and IP strategies. He has been voluntarily supporting IPAS (IP Acceleration program for Startups) by the Japan Patent Office and Pharmaceutical & Medical Startup Acceleration Program supported by the Tokyo Metropolitan Government as Legal/IP mentor.
He also works as a specially appointed professor in Tohoku University Head Office for Open Innovation Strategy.
Atsushi Usami studied pharmacology and neuroscience and received his
Ph.D. in pharmaceutical sciences from the University of Tokyo and is a
pharmacist. He worked as a consultant at MRI before joining UTEC in October
He focuses on seed/early-stage life science investments. He currently serves on the boards of Repertoire Genesis Inc., Goryo Chemical Inc., EditForce Inc., MiRTel Co. Ltd., Epigeneron Inc., Bugworks Research Inc., and OriCiro Genomics, Inc. He is a JST START promotor and a NEDO TCP mentor. He helps with commercialization and teaches seminar on industry-academia collaboration at colloquiums in the Graduate Program for Leader in Life Innovation at the University of Tokyo. He provides support for Life Science Innovation network Japan (LINK-J).
Noriaki Sakamoto graduated from the Faculty of Economy from the University of
Tokyo and entered METI. He left METI in 2008 and was appointed vice president of a
logistics company. He earned MBA from Columbia University. He was an engagement
manager at McKinsey & Company and then joined UTEC in August 2014.
He currently serves on the boards of Finatext Inc., Institution for a Global Society Corp., Retrieva, Inc., Neural Pocket Inc., JDSC Co., Liquid, Inc., and TRICOG HEALTH PTE. LTD. He has served as a corporate auditor of the Autonomous Control Systems Research Institute, Inc. / ACSL (listed on TSE Mothers in December 2018: 6232).